Products are selected by our editors, we may earn commission from links on this page.
Coenzyme Q10 shows up constantly in online posts about glucose management, but the specialists who treat diabetes are not writing it into care plans. Cecilia Low Wang, MD, an endocrinologist at UCHealth in Aurora, Colorado, told Health that CoQ10 is “not something that we hang our hat on in terms of being confident enough to recommend to our patients.” That gap between the marketing and the clinic is the whole story. The supplement is sold widely and is generally considered safe. What it lacks is the kind of trial data that would move a doctor from curious to convinced about its effect on blood sugar.
This article was created with the assistance of AI and reviewed by our editorial team for accuracy and clarity.
Some studies did find a measurable effect
The skepticism is not based on an empty research file. Megan Wroe, MS, RD, a wellness manager and registered dietitian at Providence St. Jude Medical Center, said some studies point to modest reductions in fasting blood sugar, fasting insulin, and A1C after eight to 10 weeks of daily use. A1C measures average blood sugar over roughly three months. Those reductions showed up most often in people who already had prediabetes or diabetes. So the question clinicians face is not whether any study ever found a signal. It is whether those studies were built well enough to trust the signal they found.
Your body already makes this compound
CoQ10 is not a foreign substance you are introducing. Cells produce it on their own, and it functions as a vitamin-like antioxidant involved in energy production inside the mitochondria, the structures that convert fuel into usable cellular energy. That biological role explains why the supplement industry reached for it in the first place. Most CoQ10 products on shelves are marketed for heart health rather than glucose. Blood sugar is a secondary claim that attached itself later, as the energy-production story got stretched toward metabolism. Research on the heart claims varies in quality too.
Eight to 10 weeks is a very short window
Type 2 diabetes is managed across decades. The trials cited for CoQ10 ran for a fraction of a single year. Wroe put the problem directly: many of these studies are short, so “longer-term data isn’t really there.” That mismatch matters more than it might sound. A two-month study can capture a small shift in a lab value. It cannot tell a physician whether that shift holds at month 14, whether it keeps improving, or whether it quietly reverses. For a condition measured in complications that take years to develop, two months of data answers almost none of the questions a treating clinician needs answered.
The trials often ignored diet and exercise
Low Wang and Wroe both pointed to a design problem that runs through the literature. Trials frequently do not control for diet, physical activity, or the presence of multiple chronic conditions in the same participant. Without that control, the arithmetic falls apart. A participant who starts walking more during a supplement trial may show better fasting glucose at the end of it. The spreadsheet credits the capsule. Low Wang also noted that study sizes have generally been small, which widens the margin for a result that reflects chance rather than the compound being tested.
Some of the research was formally flagged
There is a problem in this literature that goes past study design. Low Wang said some papers in this area have been retracted, and others have received an expression of concern regarding the integrity of the research. An expression of concern is a notice a journal attaches to a published paper when editors have doubts about it but have not completed an investigation. A retraction is the stronger action, withdrawing the paper outright. Either notice means a study that may still be circulating in supplement marketing is no longer something a clinician can cite. That is a different failure than a study being small.
Proposed mechanisms remain proposals
Rachel Pessah-Pollack, MD, FACE, an endocrinologist at NYU Langone Health, told Health that “lots of potential mechanisms for benefit have been proposed, ranging from improvements in insulin signaling to helping the function of beta cells in the pancreas.” Beta cells are the pancreatic cells that release insulin. Wroe pointed to the compound’s anti-inflammatory properties, particularly alongside diet and exercise changes. Some researchers have also suggested that protecting mitochondria from damage could let cells handle glucose more efficiently. All of these are hypotheses about how an unproven effect might work, which is a different thing from an explanation of a confirmed one.
The interaction risk involves cancer treatment
CoQ10 is generally regarded as safe, which is part of why it sells. Safe is not the same as inert. Low Wang said CoQ10 can interfere with some medications and therapies, with anti-cancer therapies the clearest concern. That is the reason the advice to talk to a doctor first is not a disclaimer reflex. Someone taking CoQ10 for a benefit that may not exist, while receiving treatment it could interfere with, has traded nothing for a real risk. The conversation is also where a physician can check the full medication list, which is not something a product label can do.
Doses studied run 100 to 200 milligrams daily
When CoQ10 is used with blood sugar in mind, typical doses run from 100 to 200 milligrams per day, according to Pessah-Pollack. She added that any potential benefit may be most pronounced in people who already have type 2 diabetes rather than in people without it. That last point cuts against how the supplement is usually sold. Much of the online interest comes from people trying to prevent a glucose problem rather than manage a diagnosed one. The population where the weak signal appeared at all is the population already under a doctor’s care for the condition.
The comparison that ends the argument
Pessah-Pollack drew the line clearly. “We know that lifestyle changes such as a heart-healthy diet are the first-line treatment for managing type 2 diabetes, based on excellent data,” she said. “While CoQ10 may have some benefit on blood sugar levels, the effects are significantly less and inconsistent compared to that which is achieved by diabetes medications and lifestyle interventions such as diet modifications, increased activity, and weight reduction.” The contrast is between an evidence base described as excellent and one built from short, small, partly retracted trials. Anyone weighing a CoQ10 purchase against that comparison has the information the specialists are working from.